Benzinga | Feb 23, 2021 11:33AM EST

Sanofi/Regeneron's DUPIXENT Wins Canada Approval For Atopic Dermatitis In Children Aged 6-11

* Health Canada has approved Sanofi's SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) DUPIXENT (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

* DUPIXENT is also approved in Canada to treat adult patients with severe chronic rhinosinusitis with nasal polyposis and for the treatment of severe asthma in patients 12 years and older.

* Also, both companies announced FDA approval of immunotherapy Libtayo (cemiplimab-rwlc) as monotherapy in newly diagnosed advanced lung cancer.

* Price Action: SNY is up 0.2% at $46.47, while REGN is down 2.3% at $449.8 in market trading hours on last check Tuesday.